Consonance, Jay Mohr partner to invest in deprioritized therapeutics

Through a collaboration with biotech executive Jay Mohr, Consonance Capital Partners plans to make its first therapeutics investments out of its $500 million private

Read the full 243 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE